Research programme: cancer therapeutics - Glactone Pharma

Drug Profile

Research programme: cancer therapeutics - Glactone Pharma

Alternative Names: GPA 500; GPB 600-ER; GPB 600-IO

Latest Information Update: 18 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Glactone Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer
  • Research Cancer

Most Recent Events

  • 09 May 2017 Glactone Pharma has patent protection entitled “Ether analogues of galiellalactone” in Sweden
  • 30 Jan 2017 Early research in Cancer in Sweden before January 2017 (Glactone Pharma pipeline, January 2017)
  • 30 Jan 2017 Early research in Prostate cancer (Second-line therapy or greater) in Sweden before January 2017 (Glactone Pharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top